RPC1063

( DrugBank: - / KEGG DRUG: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	42
96	Crohn disease	82

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	44

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

trials per page:

Showing 1 to 10 of 42 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-002500-91-SE (EUCTR)	01/06/2017	27/06/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063in Relapsing Multiple Sclerosis - Open Label ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0m ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2495	Phase 3	Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy;South Africa;Latvia;Moldova, Republic ...
2	EUCTR2016-003073-18-GB (EUCTR)	29/09/2016	16/09/2016	A study designed to investigate how radiolabelled RPC1063is taken up, broken down and removed from t ...	A Phase I, Single-Centre, Single Dose Oral Excretion Balance Study of [14C]-RPC1063in Healthy Male A ...	The drug is a potential treatment for adult patients with relapsing multiple sclerosis (RMS) and for ...	Product Name: [14C]-RPC1063Solution (0.1 mg/mL) for Oral Administration INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Not Recruiting			Female: no Male: yes	6	Phase 1	United Kingdom
3	NCT02797015 (ClinicalTrials.gov)	June 23, 2016	26/5/2016	Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS	A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmaco ...	Multiple Sclerosis	Drug: RPC1063	Celgene	NULL	Completed	18 Years	55 Years	All	22	Phase 1	United States
4	EUCTR2015-002500-91-HR (EUCTR)	13/06/2016	06/07/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063in Relapsing Multiple Sclerosis - Open Label ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0m ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2496	Phase 3	United States;Belarus;Portugal;Serbia;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
5	EUCTR2015-002500-91-PT (EUCTR)	06/06/2016	13/04/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063in Relapsing Multiple Sclerosis. - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCI Product Name: 1.0m ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2496	Phase 3	United States;Belarus;Portugal;Serbia;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
6	EUCTR2015-002500-91-LT (EUCTR)	31/05/2016	17/03/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063in Relapsing Multiple Sclerosis - Open Label ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0m ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2495	Phase 3	United States;Serbia;Belarus;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
7	EUCTR2015-002500-91-LV (EUCTR)	20/04/2016	19/02/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063in Relapsing Multiple Sclerosis - Open Label ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0m ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2495	Phase 3	United States;Serbia;Belarus;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
8	EUCTR2015-002500-91-EE (EUCTR)	04/04/2016	07/03/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063in Relapsing Multiple Sclerosis - Open Label ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0m ...	Celgene International II Sàrl (CIS II)	NULL	Not Recruiting			Female: yes Male: yes	2495	Phase 3	United States;Belarus;Portugal;Serbia;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
9	EUCTR2015-002500-91-IT (EUCTR)	09/02/2016	22/01/2021	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063in Relapsing Multiple Sclerosis - Open Label ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCL Product Name: 1.0m ...	CELGENE INTERNATIONAL II SàRL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2496	Phase 3	United States;Serbia;Belarus;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
10	EUCTR2015-002500-91-SK (EUCTR)	22/01/2016	28/10/2015	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063in Relapsing Multiple Sclerosis - Open Label ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0m ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2496	Phase 3	United States;Serbia;Belarus;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...

First Previous1 2 3 4 5Next Last

96. Crohn disease

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

trials per page:

Showing 1 to 10 of 82 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05470985 (ClinicalTrials.gov)	March 10, 2023	12/7/2022	A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants ...	A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacok ...	Crohn Disease	Drug: Ozanimod	Bristol-Myers Squibb	NULL	Recruiting	2 Years	17 Years	All	120	Phase 2/Phase 3	United States;Australia;Belgium;Canada;Hungary;Poland;Spain;United Kingdom
2	EUCTR2017-004294-14-FR (EUCTR)	02/12/2019	09/02/2018	Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Ac ...	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maint ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063(equivalent to ozanimod HCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	535	Phase 3	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Mo ...
3	EUCTR2017-004293-33-FR (EUCTR)	12/11/2019	09/02/2018	Multicenter Study of Oral Ozanimod as Induction Therapy in patients with Moderately to Severely Acti ...	Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of O ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063(equivalent to ozanimod HCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	675	Phase 3	Serbia;Portugal;United States;Saudi Arabia;Hong Kong;Slovakia;Greece;Spain;Ukraine;Russian Federatio ...
4	EUCTR2017-004292-31-FR (EUCTR)	05/11/2019	09/08/2019	Multicenter Study of Oral Ozanimod as Induction Therapy in patients with Moderately to Severely Acti ...	Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of O ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063(equivalent to ozanimod HCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	675	Phase 3	Belarus;United States;Taiwan;Spain;Ukraine;Ireland;Russian Federation;Israel;Switzerland;Italy;Franc ...
5	EUCTR2017-004295-55-FR (EUCTR)	08/10/2019	09/02/2018	Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s ...	A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Activ ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063(equivalent to ozanimod HCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1350	Phase 3	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Mo ...
6	EUCTR2017-004294-14-RO (EUCTR)	11/04/2019	12/05/2022	Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Ac ...	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maint ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063(equivalent to ozanimod HCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	485	Phase 3	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Mo ...
7	EUCTR2017-004292-31-RO (EUCTR)	04/02/2019	25/02/2022	Multicenter Study of Oral Ozanimod as Induction Therapy in patients with Moderately to Severely Acti ...	Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of O ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063(equivalent to ozanimod HCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	United States;Belarus;Taiwan;Spain;Ukraine;Ireland;Russian Federation;Israel;Switzerland;Italy;Franc ...
8	EUCTR2017-004295-55-PT (EUCTR)	04/02/2019	01/10/2018	Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s ...	A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Activ ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063(equivalent to ozanimod HCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1200	Phase 3	Portugal;Belarus;Hong Kong;Taiwan;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Mo ...
9	EUCTR2017-004295-55-BE (EUCTR)	13/12/2018	30/03/2018	Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s ...	A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Activ ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063(equivalent to ozanimod HCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1200	Phase 3	Belarus;Portugal;Hong Kong;Taiwan;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Mo ...
10	EUCTR2017-004294-14-DK (EUCTR)	30/11/2018	27/08/2018	Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Ac ...	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maint ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: ozanimod Product Code: RPC1063(equivalent to ozanimod HCl) INN or Proposed INN: Ozanimod ...	Celgene International II Sàrl	NULL	Not Recruiting			Female: yes Male: yes	535	Phase 3	Belarus;Portugal;Taiwan;Hong Kong;Slovakia;Greece;Ukraine;Italy;France;Puerto Rico;Denmark;Latvia;Mo ...

First Previous1 2 3 4 5…9Next Last

97. Ulcerative colitis

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

trials per page:

Showing 1 to 10 of 44 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-002308-11-ES (EUCTR)	21/07/2022	21/07/2022	A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacok ...	A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacok ...	Moderately to Severely Active Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code ...	Product Name: Ozanimod HCL Product Code: RPC1063 INN or Proposed INN: Ozanimod HCL Other descriptive na ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Phase 2;Phase 3	France;United States;Canada;Belgium;Poland;Spain;Russian Federation;Israel;Germany;Netherlands;Unite ...
2	JPRN-jRCT2021220013	01/07/2022	18/06/2022	A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Acti ...	A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacok ...	Ulcerative Colitis (UC)	Ozanimod High Dose Ozanimod Low Dose	Liu W. Jerry	NULL	Pending	>= 2age old	<= 17age old	Both	120	Phase 2-3	France;United States;Japan
3	NCT05076175 (ClinicalTrials.gov)	May 30, 2022	4/10/2021	A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Acti ...	A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacok ...	Colitis, Ulcerative	Drug: Ozanimod	Bristol-Myers Squibb	NULL	Recruiting	2 Years	17 Years	All	120	Phase 2/Phase 3	United States;Belgium;France;Germany;Israel;Japan;Poland;Russian Federation;Spain;United Kingdom
4	EUCTR2015-001600-64-AT (EUCTR)	25/07/2018	17/04/2018	The purpose of this study is to determine whether long-term RPC1063is safe and effective in the trea ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063as Therapy for Moderate to Severe ...	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl	NULL	Not Recruiting			Female: yes Male: yes	1200	Phase 3	Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Australia ...
5	EUCTR2015-000319-41-GR (EUCTR)	23/07/2018	18/04/2018	The purpose of this study is to determine whether RPC1063is safe and effective in the treatment of u ...	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063as Inducti ...	ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl (CIS II)	NULL	Not Recruiting			Female: yes Male: yes	900	Phase 3	United States;Belarus;Slovakia;Greece;Spain;Ukraine;Israel;Russian Federation;Italy;France;Australia ...
6	EUCTR2015-001600-64-GR (EUCTR)	23/07/2018	19/04/2018	The purpose of this study is to determine whether long-term RPC1063is safe and effective in the trea ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063as Therapy for Moderate to Severe ...	ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1200	Phase 3	Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Australia ...
7	EUCTR2015-000319-41-ES (EUCTR)	12/07/2018	21/05/2018	The purpose of this study is to determine whether RPC1063is safe and effective in the treatment of u ...	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063as Inducti ...	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive name ...	Celgene International II Sàrl (CIS II)	NULL	Not Recruiting			Female: yes Male: yes	900	Phase 3	France;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;Australia ...
8	EUCTR2015-001600-64-ES (EUCTR)	12/07/2018	21/05/2018	The purpose of this study is to determine whether long-term RPC1063is safe and effective in the trea ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063as Therapy for Moderate to Severe ...	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl	NULL	Not Recruiting			Female: yes Male: yes	1200	Phase 3	Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Australia ...
9	EUCTR2015-000319-41-LV (EUCTR)	22/06/2018	13/04/2018	The purpose of this study is to determine whether RPC1063is safe and effective in the treatment of u ...	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063as Inducti ...	ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25mg RPC103 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive name: ...	Celgene International II Sàrl (CIS II)	NULL	Not Recruiting			Female: yes Male: yes	900	Phase 3	United States;Belarus;Slovakia;Greece;Spain;Ukraine;Israel;Russian Federation;Italy;France;Australia ...
10	EUCTR2015-001600-64-LV (EUCTR)	22/06/2018	13/04/2018	The purpose of this study is to determine whether long-term RPC1063is safe and effective in the trea ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063as Therapy for Moderate to Severe ...	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1200	Phase 3	Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Australia ...

First Previous1 2 3 4 5Next Last